Tempus AI, Inc. entered into a definitive agreement to acquire Personalis, Inc. for a total enterprise value of $1.5 billion. Personalis shareholders will receive $16.25 per share in a transaction structured as 100% stock, with Tempus having an option to elect up to 50% cash consideration. The deal is expected to close in late 2026 or early 2027 and is subject to shareholder and regulatory approvals. Tempus AI, Inc. is a technology company that uses artificial intelligence to advance precision medicine and patient care.
